Echo Therapeutics Announces Proposed Public Offering

             Echo Therapeutics Announces Proposed Public Offering

PR Newswire

PHILADELPHIA, Jan. 31, 2013

PHILADELPHIA, Jan. 31, 2013 /PRNewswire/ --Echo Therapeutics, Inc. (Nasdaq:
ECTE), a company developing its needle-free Symphony^® tCGM System as a
non-invasive, wireless, transdermal continuous glucose monitoring system,
today announced that it intends to offer for sale its common stock in an
underwritten public offering. The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the offering
may be completed, or as to the actual size or terms of the offering.

(Logo: http://photos.prnewswire.com/prnh/20120801/NE50071LOGO )

Aegis Capital Corp. is acting as the sole book-running manager for the
offering.

The offering is being made pursuant to a shelf registration statement that
Echo previously filed with the Securities and Exchange Commission (the "SEC")
and which is effective. A preliminary prospectus supplement and accompanying
base prospectus relating to the offering will be filed with the SEC and will
be available on the SEC's website located at www.sec.gov. Electronic copies
of the preliminary prospectus supplement, when available, and accompanying
base prospectus may be obtained by contacting Aegis Capital Corp., Prospectus
Department, 810 Seventh Avenue, 18^th Floor, New York, NY, 10019, telephone:
212-813-1010 or email: prospectus@aegiscap.com.

This press release does not constitute an offer to sell, or the solicitation
of an offer to buy, these securities, nor will there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale is not permitted.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive,
wireless, transdermal continuous glucose monitoring system. Our target is
patients who could benefit from glucose monitoring in the hospital setting,
including critical care. Significant opportunity also exists for patients
with diabetes to use Symphony in the outpatient setting. Echo is also
developing its needle-free skin preparation component of Symphony, the
Prelude^® SkinPrep System, as a platform technology to enhance drug delivery
of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may
constitute forward-looking statements, including statements regarding Echo's
proposed public offering. These statements are based on current expectations
and are subject to risks and uncertainties that could cause actual future
results to differ materially from those expressed or implied by such
statements. Those risks and uncertainties include, but are not limited to,
risks related to general market conditions and the other risks and
uncertainties identified and described in more detail in Echo's filings with
the Securities and Exchange Commission. Echo undertakes no obligation to
publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104
colimpio@echotx.com 

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx

SOURCE Echo Therapeutics, Inc.

Website: http://www.echotx.com